Associated tags: ADC, Spacecraft, Investigational New Drug, Cancer, IND, Breast cancer, Patient, Pharmaceutical industry, HER2
Locations: WASHINGTON, US, CHINA, REDMOND, CHENGDU, SALVADOR, BUENOS AIRES, CANADA, SPAIN, UNITED STATES
D'Elía,
University,
Cancer,
Hematology,
Virology,
Baxter International,
Business,
Growth,
AstraZeneca,
Simcere Pharmaceutical,
Therapy,
Senior,
Patient,
Bristol Myers Squibb,
Fibrosis,
College,
Columbia Business School,
MBA,
BMS,
Boston Consulting Group,
Jie,
Drug development,
Spacecraft,
Moses Austin,
Strategic planning,
Fine chemical Dr. D'Elia's extensive experience in drug development, strategic planning, and business development is poised to propel SystImmune into its next phase of growth and innovation.
Key Points:
- Dr. D'Elia's extensive experience in drug development, strategic planning, and business development is poised to propel SystImmune into its next phase of growth and innovation.
- I look forward to working with her as we steer SystImmune towards new horizons of development and success."
- Its highly differentiated platforms discovering bi-specific and multi-specific antibodies and ADCs stand out as a testament to its innovative capabilities.
- Dr. D'Elia received her Ph.D. from the College of Pharmacy at the University of Texas at Austin and her MBA from Columbia Business School.
Retrieved on:
Tuesday, December 5, 2023
Safety,
Food,
Spacecraft,
ILD,
IND,
ADC,
Breast cancer,
Patient,
FDA,
Investigational New Drug,
HER2,
Trial of the century,
Cancer,
TNBC,
Optimism,
Pharmaceutical industry,
Medical imaging We look forward to collaborating with our clinical partners, trial treatment centers, and global regulatory agencies to contribute meaningfully to the ongoing evolution of cancer treatment."
Key Points:
- We look forward to collaborating with our clinical partners, trial treatment centers, and global regulatory agencies to contribute meaningfully to the ongoing evolution of cancer treatment."
- For more information visit poster: PS08-07 2024 San Antonio Breast Cancer conference.
- For more information visit poster: PO2-04-03 2024 San Antonio Breast Cancer conference.
- "As the clinical development of BL-M07D1 and BL-B01D1 progress, we're closer to assessing our potential to offer therapeutic pathways for patients diagnosed with breast cancer."
Retrieved on:
Saturday, October 21, 2023
ESMO,
HER2,
Congress,
European Society for Medical Oncology,
Candidate,
American Society of Clinical Oncology,
Society,
Clinical,
ADC,
HER3,
Spacecraft,
Oncology,
CMO,
Patient,
ASCO,
EGFR,
Vaccine,
Nursing The event is scheduled to take place from October 20th to 24th in Madrid, Spain, where new clinical findings will be unveiled from trials involving BL-B01D1 and BL-M07D1.
Key Points:
- The event is scheduled to take place from October 20th to 24th in Madrid, Spain, where new clinical findings will be unveiled from trials involving BL-B01D1 and BL-M07D1.
- The expanded results from these clinical trials of BL-B01D1 will include data from patients with several solid tumor types in advanced stages and having multiple cycles of prior therapies.
- The data presented at ESMO builds on previously reported clinical data at the American Society of Clinical Oncology (ASCO), and recent recognition for BL-B01D1 conferred by industry experts at the 14th Annual World ADC meeting in San Diego who recognized SystImmune's BL-B01D1 as a "Runner-Up" in the award category of "Most Promising Clinical Candidate".
- Presentations at the ESMO congress include:
Retrieved on:
Thursday, February 10, 2022
Hospital,
ADC,
Universidad Austral,
Cancer,
Time,
Catholic University of Salvador,
National Cancer Institute,
Drug Quality and Security Act,
IND,
Private Securities Litigation Reform Act,
University of Buenos Aires,
Goal,
University of Louisville School of Medicine,
Chief Medical Officer (Ireland),
Securities Exchange Act of 1934,
Therapy,
Securities Act of 1933,
Breast cancer,
Investigational New Drug,
Research,
Drug,
Control,
Gilead Sciences,
University,
School,
Pharmacological Research,
Pharmaceutical industry,
Medical device,
Medicine as Chief Medical Officer, effective on February 7, 2022.
Key Points:
- as Chief Medical Officer, effective on February 7, 2022.
- Dr. Olivo joined SystImmune, Inc. from Protara Therapeutics, Inc. where he served as the Chief Medical Officer and led the advancement of the early-stage clinical effort in the area of non-muscle invasive bladder cancer.
- "I feel fortunate to join SystImmune, Inc. at this stage," said Dr. Olivo.
- We do not offer patient-specific treatment advice and if you have medical conditions, please see your own medical doctor or healthcare provider.
